Comparison of the effects of Omadacycline and Moxifloxacin in the treat-ment of community-acquired pneumonia
Objective To compare the efficacy of Omadacycline and Moxifloxacin in the treatment of community-acquired pneumonia.Methods A total of 156 patients with community-acquired pneumonia admitted to Northern Jiangsu People's Hospital from May 2022 to November 2023 were selected and they were divided into observation group and control group according to the random number table method,with 78 cases in each group.On this basis,the control group was treated with Moxifloxacin,and the observation group was treated with Omadacycline.The two groups were treat-ed for 7-14 days.Clinical efficacy,improvement time of clinical symptoms,inflammatory indicators(white blood cell count[WBC],C-reactive pro-tein[CRP],procalcitonin[PCT],and interleukin-6[IL-6]levels),pathogen clearance,and adverse reactions were compared between the two groups.Results In the observation group,two cases fell off during treatment.The clinical efficacy of the observation group was better than that of the control group,and the difference was statistically significant(P＜0.05).Before treatment,there was no significant difference in inflammation indexes be-tween the two groups(P＞0.05).After treatment,WBC,CPR,PCT,and IL-6 levels of the two groups were lower than before treatment,and WBC,CRP,and PCT in the observation group were lower than the control group,the differences were statistically significant(P＜0.05),while there was no significant difference in the IL-6 level of the two groups(P＞0.05).There was no significant difference in pathogen clearance between the two groups(P＞0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion Compared with Moxifloxacin,Omadacycline is effective in the treatment of community-acquired pneumonia,which can promote the relief of clinical symptoms,reduce inflammatory response,and is safe and feasible.
NETL
NSTL
万方数据
